Last $7.11 USD
Change Today -0.04 / -0.56%
Volume 22.0K
As of 8:10 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

agile therapeutics inc (AGRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/23/14 - $12.55
52 Week Low
05/23/14 - $5.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

agile therapeutics inc (AGRX) Related Businessweek News

No Related Businessweek News Found

agile therapeutics inc (AGRX) Details

Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

11 Employees
Last Reported Date: 05/23/14
Founded in 1997

agile therapeutics inc (AGRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $390.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.0K
Compensation as of Fiscal Year 2013.

agile therapeutics inc (AGRX) Key Developments

Agile Therapeutics Approves Restated Certificate of Incorporation

On May 29, 2014, Agile Therapeutics, Inc. filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware in connection with the closing of the Company's initial public offering of shares of its common stock. The company's board of directors and stockholders previously approved the Restated Certificate effective as of and contingent upon the closing of the company's initial public offering. The Restated Certificate amends and restates in its entirety the company's second amended and restated certificate of incorporation, as amended. The Restated Certificate, among other things: authorizes 150,000,000 shares of common stock; eliminates all references to the previously existing series of preferred stock; authorizes 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; provides that the Board be divided into three classes with staggered three-year terms, with one class of directors to be elected at each annual meeting of the company's stockholders; provides that directors may only be removed with cause and only upon the affirmative vote of holders of at least 75% of the voting power of all then-outstanding shares of capital stock of the company entitled to vote generally in the election of directors; provides that only the Board, the chairman of the Board, if one is appointed, or the chief executive officer may call a special meeting of stockholders; and requires that any action instituted against the company's officers or directors in connection with their service to the company be brought in the State of Delaware. Effective as of May 29, 2014, the Company adopted amended and restated bylaws in connection with the closing of the Company's initial public offering of shares of its common stock. The Board and the Company's stockholders previously approved the Restated Bylaws effective as of and contingent upon the closing of the Company's initial public offering. The Restated Bylaws amend and restate, in their entirety, the Company's amended and restated bylaws. The Restated Bylaws, among other things: (i) provides that, subject to limited exceptions, vacancies on the Board shall only be filled by the remaining members of the Board; (ii) eliminates the ability of the Company's stockholders to take action by written consent in lieu of a meeting; and (iii) requires advance written notice of stockholder proposals and director nominations.

Agile Therapeutics, Inc.(NasdaqGM:AGRX) added to NASDAQ Composite Index

Agile Therapeutics, Inc. will be added to the NASDAQ Composite Index.

Agile Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Agile Therapeutics, Inc. filed its S-1/A on Apr 17, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGRX:US $7.11 USD -0.04

AGRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 26.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGILE THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at